A database of FDA approved therapeutic peptides and proteins
| This page displays user query in tabular form. |
1426 details |
| Primary information | |
|---|---|
| ThPP ID | Th1071 |
| Therapeutic Peptide/Protein Name | Pancrelipase |
| Sequence | Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDI view full sequnce in fasta |
| Functional Classification | Ia |
| Molecular Weight | 131125.6 |
| Chemical Formula | C5850H8902N1606O1739S49 |
| Isoelectric Point | 10.44 |
| Hydrophobicity | N.A. |
| Melting Point (℃) | 48-54 |
| Half Life | Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so ther |
| Description | Pancrelipase is an enzyme mixture isolated from porcine or bovine pancreas, sometimes called pancreatin. It contains 3 enzymes: amylase, lipase, and a protease (chymotrypsin). Pancrelipase is marketed under several brand names such as Ultresa and Viokace. |
| Indication/Disease | For treatment of exocrine pancreatic insufficiency in cystic fibrosis (Ultresa), chronic pancreatitis (Viokace in combination with a proton pump inhibitor), and pancreatectomy (Viokace in combination with a proton pump inhibitor) |
| Pharmacodynamics | Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool. |
| Mechanism of Action | The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. |
| Toxicity | Overdose symptoms may include diarrhea or stomach upset. The most common adverse reactions seen are ear, neck, and abdominal pain; headache, nasal congestion, and beta-hemolytic streptococcal infection. |
| Metabolism | Pancrelipase acts locally, so there is minimal metabolism. |
| Absorption | Pancrelipase is not significantly absorbed from the gastrointestinal tract. |
| Volume of Distribution | N.A. |
| Clearance | Pancrelipase is not significantly absorbed, so there is minimal clearance from the body. |
| Categories | Gastrointestinal Agents and Enzyme Replacement Agents |
| Patents Number | N.A. |
| Date of Issue | N.A. |
| Date of Expiry | N.A. |
| Drug Interaction | N.A. |
| Target | N.A. |
| Information of corresponding available drug in the market | |
| Brand Name | ULTRASE |
| Company | Axcan Pharma |
| Brand Discription | ULTRASE (pancrelipase) Capsules are orally administered and contain 250 mg of enteric-coated microspheres of porcine pancreatic enzymeconcentrate, predominantly pancreatic lipase, amylase, and protease. |
| Prescribed for | ULTRASE (pancrelipase) Capsules are indicated for patients with partial or complete exocrine pancreatic insufficiency caused by cystic fibrosis, Chronic pancreatitis due to alcohol, Obstruction, Other pancreatic disease, Poor mixing |
| Chemical Name | N.A. |
| Formulation | Each ULTRASE (pancrelipase) Capsule contains 4500 USP units of lipase; 25000 USP units of protease; 20000 USP units of amylase. It contains povidone, talc, sugar, methacrylic acid copolymer (Type C), triethyl citrate, simethicone emulsion. |
| Physcial Appearnce | Capsules Enteric-Coated Microspheres |
| Route of Administration | Oral route |
| Recommended Dosage | Initial dosing of pancreatic enzyme supplements should begin with 500 lipase U/kg/meal using enteric-coated microsphere products. |
| Contraindication | Pancrelipase capsules are contraindicated in patients known to be hypersensitive to pork protein. Pancrelipase capsules are contraindicated in patients with acute pancreatitis or with acute exacerbations of chronicpancreatic diseases. |
| Side Effects |  Extremely high doses of exogenouspancreatic enzymes have been associated with hyperuricosuria andhyperuricemia, |
| Useful Link | http://www.rxlist.com/ultrase-drug.htm |
| PubMed ID | 28099252, 27560634, 26748629, 26726093, 26709820, 26495784, 26495776, 26150571, 26036459 |
| 3-D Structure | Th1071 (View) or (Download) |